News Releases
Jun 26, 2023
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer Read more
May 11, 2023
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Read more
May 9, 2023
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer Read more
Apr 25, 2023
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma Read more
Mar 13, 2023
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer Read more
Mar 9, 2023
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Read more
Feb 16, 2023
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer Read more
Jan 5, 2023
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 Read more
Jan 3, 2023
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference Read more